Categorization of outcomes and genomic annotation of the study population. (A) Kaplan-Meier plots of OS for patients with AML treated with venetoclax in combination with either DNMTi’s or LDAC. n = 81, P = .52 (log-rank) for comparison between different combinations. (B) Kaplan-Meier plots for relapse-free survival for patients with AML achieving response (CR, n = 35; CRi, n = 17; and MLFS, n = 7) after treatment with either venetoclax in combination with DNMTi’s or LDAC. n = 59, P = .93 (log-rank) for comparison between different combinations. (C) Categorization of patients into those achieving durable remission (group A, n = 18), remission then relapse with adaptive resistance (group B, n = 25), primary refractory disease (group C, n = 20), or into an uncategorized group when the criteria were not met for any of the other categories (n = 18). The presence of adverse cytogenetic risk, complex karyotype, del(17p), indicated mutations, study ID number, best response (CR, CRi, MLFS, resistant disease [RD], or nonevaluable [NE]), cytotoxic therapy received (AZA, azacitidine; DEC, decitabine; or LDAC), and prior exposure to DNMTi are shown for each case. Shown to the right of the plot are the number of cases achieving (dark gray) or not achieving (light gray) CR or CRi.